Andrew Dike
Chief Strategy Officer Biomate AI
Seminars
Wednesday 22nd July 2026
One Platform, Every Step: LLM-Orchestrated Drug Discovery from Target to Clinic
9:45 am
- LLM-driven workflow orchestration — researchers describe their scientific question in plain language; BioMate interprets intent, selects from 4,000+ biomedical workflows across therapeutic areas, and executes end-to-end without manual tool switching or scripting
- Built for translational science — native connectivity across leading biomedical databases and instrument connectors, spanning biomarker discovery, patient stratification, and mechanism/target analysis, through genomics and proteomics to ADMET and PBPK — uninterrupted flow from disease biology to clinic
- Proven acceleration across the translational continuum — from rare autoimmune patient stratification to IND-enabling compound profiling, BioMate compresses multi-step programs into hours by removing the handoffs that slow science down
